도파민 퀴논(DAQ) 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Dopamine Quinone (DAQ) Market

The future of the global dopamine quinone (DAQ) market looks promising with opportunities in the neuroscience research, drug quality control, and biochemical research markets. The global dopamine quinone (DAQ) market is expected to reach an estimated $80.3 million by 2035 from $50.9 million in 2027 with a CAGR of 3.6% from 2027 to 2035. The major drivers for this market are the increasing demand for high purity biochemical compounds, the rising research activities in neuroscience applications, and the growing use in pharmaceutical and diagnostic studies.

• Lucintel forecasts that, within the type category, more than 95% is expected to witness higher growth over the forecast period due to greater purity for more precise analysis.
• Within the application category, neuroscience research is expected to witness the highest growth over the forecast period due to rising interest in neurodegenerative disease research, specifically in dopamine quinones.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increased neuroscience research, particularly in funding and academia.

Emerging Trends in Dopamine Quinone (DAQ) Market

Dopamine Quinones (DAQs) are anticipated to evolve beyond their current use as research reagents in neurochemistry, biosensing and pharmaceutical and food quality testing by 2027. According to Lucintel, continued focus on streamlining laboratory procedures has created a demand for reliable and safe reference materials.

• Standardization of Analysis: In 2025, LC-MS methods for the analysis of DAQs were published. During the same year, NIST-like standards and practices for DAQs were published. These developments, as well as alignment to ISO/IEC 17025:2017, will boost the adoption of DAQs for laboratory testing and analysis. This will occur primarily in the contracts and regulatory testing sector through 2030.
• DAQ Biosensors: The emphasis on the development of biosensors, including microfluidic systems, for the detection of DAQs will continue to decrease analysis time and improve the portable nature of testing.
• Neurodegeneration: 2025 outlooks suggest that DAQ will be crucial to understanding oxidative stress in neurodegeneration. This will continue to create a need for DAQ standards and inhibitors, as well as pathway screening.
• Pharmaceutical Process Control: The 2025-2026 time frame will see more stringent control over catechol oxidation during the manufacturing and storage of biologics. This will increase the need for characterization of DAQ and its related methods.
• New Markets: Dopamine oxidation is of interest to food and drug analysis in 2025. This will stimulate research into neurodegenerative diseases. The need for DAQ will lessen the market's dependence on neuroscience funding.

DAQ is a focused market, but its opportunities are increasing. Stable DAQ standards will be in high demand. Like the previous year's report, growth is expected to come from higher margin services rather than standard sales. The best opportunities will go to companies that integrate DAQ chemistry with related services.

Recent Developments in the Dopamine Quinone (DAQ) Market

• Commercial Coatings: A January 2025 article highlighted the development of a family of dopamine-based coatings for metal adhesion. The article represents the first commercially available coating for metal corrosion and is expected to drive increased demand for DAQ. It is expected that during the next 3 to 5 years the coating will need to demonstrate commercial viability.
• Biomaterials: An April 2025 article presented laboratory data for a hydrogel system based on a DAQ derivative that achieved 90% tissue adhesion. Wound care and medical device closure products based on DAQ and similar chemicals would command a premium in the marketplace.
• Specialty Chemicals: During 2025, a number of Asian chemical companies completed the construction of facilities to produce Intermediates of DAQ. It is expected that the increased supply would further reduce the barriers for entry to develop end-use products.
• Government-funded Translational Research: The EU's Horizon Europe program awarded up to €4 million in 2025 to fund bioinspired adhesives and coatings research. It is expected that other government funding will help commercialize DAQ-based technologies.
• Advancement of Analytical Methodology: In 2026, several labs published methods to analytically determine the concentration of Dopamine Quinone. The availability of such methods should facilitate the release of batches of DAQ containing pharmaceuticals and other biomedical products. Continued research should facilitate tracking of the stability and regulatory documentation for such products.

By 2027, various dependable sources for DAQ should be available. Improved standardization and stability should facilitate broader market adoption, especially in research, coatings and medical adhesives.

Strategic Growth Opportunities in the Dopamine Quinone (DAQ) Market

Opportunities in the DAQ market will exist outside laboratory markets by 2026. Of particular interest are markets for melanin and other advanced materials, as well as electrochemical sensors and other interfaces. While Lucintel believes opportunities exist in these markets, the first sale of DAQ will be determined by the synthesis of commercially viable quantities of DAQ and determination of the toxicological profile of the material.

• Biosensors: DAQ can be incorporated into sensors for hormones, neurotransmitters, and other biochemical species as well as reactive oxygen species. Of particular interest is the detection of dopamine and other related species. A 2025 report indicated that electrodes incorporating DAQ enabled detection of dopamine and related species with limit of detection in the low micromolar range. It is expected that the market for portable and hand-held diagnostic sensors will create opportunities for DAQ-based products.
• Melanin: DAQ and other quinones can be complexed to synthesize melanin. DAQ-based melanin may be used to coat various substrates and provide adhesion as well as protect the coating from photodegradation. It is expected that DAQ based melanin will find use in biomedical and other consumer product markets.
• Pharmaceuticals: DAQ can be used in reference and reagent standards for controlling the degradation and oxidation of dopamine in pharmaceutical synthesis and processing. There is an existing, and growing, need for regulatory laboratories to test pharmaceutical products. It is expected that regulatory laboratories will continue to process an increasing number of samples.
• Neuro Pharmaceuticals: Advancing our understanding of neurodegenerative disorders requires a deeper understanding of mechanisms such as dopamine oxidation and protein modification. The WHO estimated the global case load for Parkinson's disease at 8.5 million for 2019 with ongoing basic and pharmaceutical research (February 2025 status). Contract research organizations (CROs) can develop models based on client requirements.
• Sustainable Synthesis: Like most oxidants, the reducing agents and base metals catalysts employed in DAQ synthesis can be replaced by enzymes. Alternatively, electrochemical methods can be used to generate hydrogen peroxide in situ. The 30% reduction in reaction energy achieved in a 2026 process demonstration project provides encouragement for further research. Given regulatory trends, customers in the near-term will be willing to pay a premium for traceability and reliability in pharmaceutical supply.

Although new applications will drive modest growth in the DAQ market, the main opportunities will be derived from performance, rather than volume. For new customers, especially in the pharmaceutical market, suppliers that partner with specialized research organizations to provide application support and purity will be able to charge a premium.

Dopamine Quinone (DAQ) Market Drivers and Challenges

DAQ market is ushered by changes in technology and biomedical sciences, together with changes in economy and demands and expectations of society and government .DAQ and related products find uses in various fields of research and become more and more important. Among others, Lucintel mentions innovative research as one of the driving forces. Clinical practice and related areas of research remain key markets.

The factors responsible for driving this market include:

• Advancing Biomedical Research: In recent years, the interest in the role of DAQ in oxidative stress and neuronal damage and protein modification, and in neurodegenerative processes has increased. A number of research projects dealt with the role of DAQ and the toxicity of dopamine and other related compounds. Demand for DAQ of analytical purity and other related compounds has increased. In view of the increasing research interest in neurological and neurodegenerative diseases and in particular in Parkinson's and Alzheimer's diseases, it may be expected that the supply of DAQ and related compounds will improve in the next few years.
• Biosensors: DAQ can allow biosensors to detect biomolecules and enzymes, and work as an oxidation sense reagent. There is expected interest in quinone detection in 2026, for further development of sensor platforms, to reduce the response time below 1 minute. Such sensors can be utilized in various clinical and laboratory tests, food and environment analysis. It is expected that during the next 3-5 years, a significant increase in the number of sensor applications will be observed. This increase can be explained by the improvement in the technologies related to the miniaturization of electronics, and sensors.
• Pharmaceutical and Chemical Sciences: Quinones, and in particular DAQ, are of interest to the pharmaceutical and chemical sciences. In 2025, the presence of more than one research drug for neurological conditions at a pre-clinical and clinical research stage, will create the need for high quality reference standards, further increasing the interest for DAQ. Overall, the expansion of the neurological drug research pipelines will create an increased interest for DAQ in the next 3-5 years, with the majority of the consumers being research-related end-users.
• Sustainability and Chemistry: As interest grows in sustainable chemistry, laboratory practices are evolving to reduce the use of hazardous solvents and wasteful reactions and increase the efficiency of material usage in the preparation of DAQs. Since April 2025, multiple research laboratories have implemented the 3R principle (i.e. replacement, reduction, and refinement) in their experimental practices. In the coming 3 to 5 years, other research laboratories are likely to implement similar practices based on the demand for doping agents and other materials used in research, particularly in the pharmaceutical industry, to be sourced from suppliers that minimize their impact on the environment.
• Reliability of Manufacturing and Analysis: The reliability of analysis and purification has improved to the extent that some suppliers are able to consistently provide Dopamine Quinone. During the same time period, fully automated laboratories will become commonplace. Improved automation, process control, and management of variability will facilitate better management of shelf life and reduce the need for repetitive testing.

The challenges facing this market include:

• Chemical Instability and Handling: Dopamine Quinone (DAQ) is quite an unstable chemical and can be converted to other chemical species quickly. In 2025, many laboratories reported that to maintain the integrity of their DAQ assays, they had to employ at least two controls, e.g. storage at low temperatures, and shielding from light and atmospheric oxygen. Quick chemical changes increase the uncertainty in results and increase the costs of assays. Reducing the uncertainty requires improvement in the packing and delivery of DAQ by the supplier within the next 3-5 years.
• Standardization and Regulatory Issues: Commercial chemical standards define the requirements for purity and impurities as well as reference methods of analysis. In the absence of such standards, comparability and reproducibility of analytical results are compromised. Regulatory classification of DAQ is also dependent on its end-use, e.g. as a research chemical or an analytical standard or a pharmaceutical intermediary. Reproducibility of results is likely to catalyze the development of Chemical Standards within the next 3-5 years.
• Small Markets and High Prices: Due to requirements of the synthesis and purification of DAQ, as well as its sensitivity to changes during storage, costs of production increase and economies of scale do not apply. DAQ will be expensive to produce and, in comparison to similar catechol-based reagents, pricey for the smaller labs in 2025. Lack of repeated, large-scale consumption discourages large-scale production. DAQ may find more widespread use in the next 3-5 years if improvements in large-scale production do not affect purity of the product. These improvements may be found through more innovative methods of synthesis.

Current interest in DAQ, through various fields of study such as pharmaceuticals, biosensors and other frontier research, fosters anticipation of growth in the DAQ market. These fields promote the development of new manufacturing processes that increase the efficiency and purity of DAQ. Although DAQ remains a highly-priced and unstable product, continued research will promote more commercial applications. It is anticipated that the research and development of methods to control and stabilize DAQ will generate a more commercialized DAQ market.

List of Dopamine Quinone (DAQ) Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies dopamine quinone (DAQ) market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dopamine quinone (DAQ) market companies profiled in this report include-

• Simson Pharma
• Chemicea Pharma
• Clearsynth
• Sigma-Aldrich
• Pharmaffiliates

Dopamine Quinone (DAQ) Market by Segment

The study includes a forecast for the global dopamine quinone (DAQ) market by type, application, and region.

Dopamine Quinone (DAQ) Market by Type [Value ($M) from 2019 to 2035]:

• More than 95%
• Less than 95%

Dopamine Quinone (DAQ) Market by Application [Value ($M) from 2019 to 2035]:

• Neuroscience Research
• Drug Quality Control
• Biochemical Research

Dopamine Quinone (DAQ) Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Dopamine Quinone (DAQ) Market

Currently, dopamine quinone (DAQ) is a specialized biochemical intermediate and, therefore, is not an individual marketable product. However, between 2025 and 2027, there is potential development of pharmaceutical processes and manufacturing controls, and supply chains for catecholamines and other biomaterials. Recent work by Lucintel has identified very few, if any, public reports and, thus, regulatory and company reports are more relevant.

• United States: In 2025, the U.S. Food and Drug Administration (FDA) continued focusing on the quality of drug substances and the resiliency of drug substance supply chains. Other U.S. agencies continued funding research on dopamine oxidation and bioadhesives. The National Institutes of Health (NIH) was allocated approximately $47.1 billion in fiscal 2025. Researchers utilized these funds to support and engage in bio-medical research, including development of novel adhesives and drug substances. The NIH support and research is anticipated to continue to enhance and support the production and manufacturing of these drug substances and bio-adhesives, thus influencing DAQ in the long term.
• China: In 2025, China continued to develop and support a pharmaceutical industry focusing on advanced pharmaceutical intermediates. The 2025 strategic planning document of China's central government announced a 7% or higher increase in national research and development spending. Chemical manufacturing industries in China continued to construct and expand their manufacturing capacity. It is anticipated that in the next three to five years, China will be able to produce and supply a larger quantity of advanced pharmaceutical intermediates including those related to dopamine.
• Germany: The requirements of EU laws, e.g. REACH, and GMP continued governing the German pharmaceutical sector. German chemical companies shifted to more efficient and less polluting production methods. As of February 2025, BASF reported expectations of about 65.3 billion euros of sales in the year 2024, illustrating the importance and dimension of Germany's chemical industry. The disciplined and rigorous regulations of the German chemical industry and established infrastructure will attract research and production of DAQ in Germany.
• India: The Indian government's continued (February 2025) initiative to create and strengthen the domestic production of active pharmaceutical ingredients and intermediates through incentives and other schemes enhanced India's potential to produce dopamine and related intermediates, and decreased the dependency on imported intermediates.
• Japan: For fiscal year 2025, the Japanese government allocated approximately 5.5 trillion Japanese Yen (April 2025) for fundamental research. University researchers and materials companies focused on bio-inspired catechol syntheses. Japan maintained its stringent regulation on the quality of pharmaceuticals. Public and university research will support advanced materials and DAQ-related research.

Features of the Global Dopamine Quinone (DAQ) Market

• Market Size Estimates: dopamine quinone (DAQ) market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: dopamine quinone (DAQ) market size by type, application, and region in terms of value ($B).
• Regional Analysis: dopamine quinone (DAQ) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the dopamine quinone (DAQ) market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dopamine quinone (DAQ) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dopamine quinone (DAQ) market by type (more than 95% and less than 95%), application (neuroscience research, drug quality control, and biochemical research), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Dopamine Quinone (DAQ) Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 More than 95% : Trends and Forecast 2019 to 2035
• 4.4 Less than 95% : Trends and Forecast 2019 to 2035

5. Global Dopamine Quinone (DAQ) Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Neuroscience Research : Trends and Forecast 2019 to 2035
• 5.4 Drug Quality Control : Trends and Forecast 2019 to 2035
• 5.5 Biochemical Research : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Dopamine Quinone (DAQ) Market by Region

7. North American Dopamine Quinone (DAQ) Market

• 7.1 Overview
• 7.2 North American Dopamine Quinone (DAQ) Market by Type
• 7.3 North American Dopamine Quinone (DAQ) Market by Application
• 7.4 The United States Dopamine Quinone (DAQ) Market
• 7.5 Canadian Dopamine Quinone (DAQ) Market
• 7.6 Mexican Dopamine Quinone (DAQ) Market

8. European Dopamine Quinone (DAQ) Market

• 8.1 Overview
• 8.2 European Dopamine Quinone (DAQ) Market by Type
• 8.3 European Dopamine Quinone (DAQ) Market by Application
• 8.4 German Dopamine Quinone (DAQ) Market
• 8.5 French Dopamine Quinone (DAQ) Market
• 8.6 Italian Dopamine Quinone (DAQ) Market
• 8.7 Spanish Dopamine Quinone (DAQ) Market
• 8.8 The United Kingdom Dopamine Quinone (DAQ) Market

9. APAC Dopamine Quinone (DAQ) Market

• 9.1 Overview
• 9.2 APAC Dopamine Quinone (DAQ) Market by Type
• 9.3 APAC Dopamine Quinone (DAQ) Market by Application
• 9.4 Chinese Dopamine Quinone (DAQ) Market
• 9.5 Indian Dopamine Quinone (DAQ) Market
• 9.6 Japanese Dopamine Quinone (DAQ) Market
• 9.7 South Korean Dopamine Quinone (DAQ) Market
• 9.8 Indonesian Dopamine Quinone (DAQ) Market

10. ROW Dopamine Quinone (DAQ) Market

• 10.1 Overview
• 10.2 ROW Dopamine Quinone (DAQ) Market by Type
• 10.3 ROW Dopamine Quinone (DAQ) Market by Application
• 10.4 Middle Eastern Dopamine Quinone (DAQ) Market
• 10.5 South American Dopamine Quinone (DAQ) Market
• 10.6 African Dopamine Quinone (DAQ) Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Dopamine Quinone (DAQ) Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Simson Pharma
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Chemicea Pharma
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Clearsynth
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Sigma-Aldrich
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Pharmaffiliates
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Cayman Chemical
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Tocris Bioscience
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Santa Cruz Biotechnology
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Aladdin Biochemical Technology
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Macklin Biochemical
  • Company Overview
  • Dopamine Quinone (DAQ) Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us